Cardiol Therapeutics Inc.

TSX:CRDL Rapporto sulle azioni

Cap. di mercato: CA$174.2m

Cardiol Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che Cardiol Therapeutics aumenterà gli utili e i ricavi rispettivamente del 22.9% e 76.1% all'anno, mentre si prevede che l'EPS crescerà del 22.5% all'anno.

Informazioni chiave

22.9%

Tasso di crescita degli utili

22.5%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili53.4%
Tasso di crescita dei ricavi73.7%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento20 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Jan 20
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Aug 10
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Apr 17
We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03
Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Previsioni di crescita degli utili e dei ricavi

TSX:CRDL - Stime future degli analisti e dati finanziari passati (CAD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20261-42-33-334
12/31/2025N/A-41-35-345
12/31/2024N/A-37-25-255
9/30/2024N/A-36-26-26N/A
6/30/2024N/A-29-22-22N/A
3/31/2024N/A-30-22-22N/A
12/31/2023N/A-28-25-25N/A
9/30/2023N/A-28-31-31N/A
6/30/2023N/A-30-30-30N/A
3/31/2023N/A-29-27-27N/A
12/31/2022N/A-31-27-27N/A
9/30/2022N/A-30-19-19N/A
6/30/2022N/A-32-23-23N/A
3/31/20220-32-27-27N/A
12/31/20210-32-24-24N/A
9/30/20210-35-22-22N/A
6/30/20210-30-19-19N/A
3/31/2021N/A-27-14-14N/A
12/31/2020N/A-21-9-9N/A
9/30/2020N/A-14-10-10N/A
6/30/2020N/A-13-9-9N/A
3/31/2020N/A-13-10-10N/A
12/31/2019N/A-14-12-11N/A
9/30/2019N/A-20-17-17N/A
6/30/2019N/A-21-16-16N/A
3/31/2019N/A-19-15-15N/A
12/31/2018N/A-16-11-11N/A
9/30/2018N/A-8-3-3N/A
6/30/2018N/A-3N/A-2N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CRDL rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CRDL rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CRDL rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che CRDL non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che CRDL non avrà alcun fatturato il prossimo anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CRDL è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita